Ebos lifted profit 21% in FY22 but analysts are asking how long it can last

Ebos lifted profit 21% in FY22 but analysts are asking how long it can last
Chief executive John Cullity said covid could be a tailwind or a headwind by the end of FY23. (Photo: Ebos)
Dan Brunskill
Ebos Group’s annual revenue has climbed above A$10 billion (NZ$11.15b) as the pandemic has increased demand for pharmaceutical products, but analysts are asking if that trend could reverse.  The healthcare and animal products company has been a beneficiary of the covid-19 pandemic, growing its revenue from A$8.7b in 2020 to A$10.7b in 2022.This year alone it grew revenue by 16.6%, underlying earnings by 19% and underlying net profit by 21.3% to A$228.2 million.Not all the growth has been driven by the pandemic however, Forsyth Barr r...

More Markets

Five reasons gold is surging toward US$5,000 an ounce
Markets

Five reasons gold is surging toward US$5,000 an ounce

Buying the precious metal has become the antidote for market jitters.

NZ sharemarket ends week down almost 2%
Markets Market Close

NZ sharemarket ends week down almost 2%

The S&P/NZX 50 Index closed at 13,448.24, down 108.63 points or 0.8%.

Graham Skellern 23 Jan 2026
Mainland Group sale expected to settle in the first quarter
Primary Sector

Mainland Group sale expected to settle in the first quarter

The Fonterra deal had been tipped to go through in the first half of this year.

Riley Kennedy 23 Jan 2026
Increased Chinese marriages, more babies expected
Primary Sector

Increased Chinese marriages, more babies expected

The birth rate in the People's Republic of China fell to a record low.

Riley Kennedy 23 Jan 2026